Arterial pressure (AP) and inter-beat interval (IBI) length are under autonomic nervous system control. The control mechanisms can be investigated by transfer function analysis. It is not known if this type of analysis may be helpful in monitoring depth of sedation. In an open-label, uncontrolled investigation, the effect of midazolam on the transfer function between AP and IBI, and on spectral indices of AP and heart rate (HR) variability (APV, HRV) were assessed in the absence and presence of the benzodiazepine antagonist flumazenil. We studied 11 healthy male volunteers. After an initial control period of 60 min, we studied three consecutive periods, each of 60 min duration, with progressively increasing concentrations of midazolam (0.02, 0.06, 0.14 mg kg -1 h -1 ). A final 60-min period during administration of flumazenil 0.004 mg kg -1 h -1 and while the agonist was still present was also studied. To confirm midazolam-induced central nervous system effects, electroencephalography was performed and Ramsay sedation scores were determined. With increasing dose of midazolam, the high frequency (0.15-0.4 Hz) component of the transfer function between AP and IBI decreased progressively (mean 26.5 (SEM 3.7), 19.2 (2.9), 12.8 (1.7), 8.4 (1.6) ms mm Hg -1 ). This effect was antagonized by flumazenil (21.5 (3.2) ms mm Hg -1 ). Other indices (e.g. HRV, APV) did not reveal such a clear response to midazolam dose and flumazenil application. Thus in healthy male volunteers, the transfer function between AP and IBI in the parasympathetically dominated high frequency range varies according to benzodiazepine agonism and antagonism. This finding has potential implications for monitoring the effects of benzodiazepines.
Benzodiazepines are important hypnotic, sedative, amnesic several sedation scores, description of motor responses to standard nursing procedures and electroencephalogram and anxiolytic drugs. [1] [2] [3] In intensive care medicine the benzodiazepine agonist midazolam is used frequently in (EEG) and autonomic nervous system variables have been proposed. patients requiring ventilatory support. Although midazolam has a relatively short half-life in healthy volunteers (approxiAutonomic indices have the advantage that they are independent of verbal report and other muscular responses mately 2-3 h), active midazolam metabolites may be of significance in patients suffering from multiple organ and thus may be determined during neuromuscular block.
Common autonomic nervous system indices, such as AP failure. 4 In such circumstances, patients are at increased risk of oversedation. Oversedation enhances the likelihood and HR, are easy to identify but are not specific to the impact of anaesthetic drugs on the autonomic nervous of future benzodiazepine withdrawal problems and favours autonomic nervous system dysfunction, resulting in hypo-system. Spectral analysis of AP variability (APV) and HR variability (HRV), and in particular transfer function analysis tension, respiratory depression and disturbed bowel motility. In contrast, undersedation may cause ventilatory problems, between AP and inter-beat interval (IBI) length, may provide important additional information on autonomic nervous subject patients to pain and discomfort, and may cause stress-related activation of the autonomic nervous system, system control. 5 6 Transfer function analysis between AP and IBI not only allows the user to estimate the magnitude with subsequent increases in arterial pressure (AP), heart rate (HR) and oxygen demand. In routine care, clinicians of IBI changes associated with AP variations, but also differentiates between slow (less than 0.15 Hz) and fast need to grade the sedative effects of drugs. For this purpose, (greater than 0.15 Hz) components of this association. 5 (0.01 mg kg -1 over the remaining 58 min). During the third and fourth experimental periods, midazolam 0.06 and However, the role of these techniques for monitoring the sedative effects of drugs needs to be investigated further. 0.14 mg kg -1 were given by bolus and infusion as above.
The total dose of midazolam for a subject with a body Thus, we performed a volunteer study to assess the effects of midazolam on APV, HRV and on transfer functions weight of 70 kg was 15.4 mg. During the fifth experimental period, midazolam infusion was stopped and the benzodiazbetween AP and IBI using a simple dose regimen which also included administration of the benzodiazepine antagonist epine antagonist flumazenil was given i.v. (0.002 mg kg -1 as a bolus followed by 0.002 mg kg -1 as a constant infusion flumazenil. An electroencephalogram (EEG) was assessed simultaneously as a standard technique for monitoring over the remaining hour) while the agonist was still present.
Plasma samples were obtained 30 min after the start of sedative effects.
each period and at the end of each period (60 min). Samples were centrifuged and stored at -20°C for HPLC analyses
Subjects and methods
of midazolam 7 with a detection limit of 1 ng ml -1 . During The study was performed according to the principles of the the flumazenil period, the 60-min sample was omitted. Declaration of Helsinki and was approved by the Local Averages of 30-and 60-min plasma midazolam concentraEthics Committee of the Department of Medicine, Univer-tions were calculated. sity Hospital of Basel.
We studied 11 male, healthy, non-smoking volunteers Monitoring of cardiovascular data (aged 23-42 yr). All volunteers had a normal physical During each infusion period, two 5-min blocks of cardioexamination, and electrocardiography, routine blood chemvascular and ECG data were recorded simultaneously. istry and haematology and urine analysis were normal, with Non-invasive arterial finger AP was assessed continuously no evidence or history of illicit drug abuse or use of using the Finapres system. 8 Beat-to-beat systolic and sedatives. Participants signed an informed consent before diastolic AP were determined offline from the Finapres participating in the study.
analogue output. Single-lead electrocardiogram was stored Subjects entered the hospital at 08:00 after a light on personal computer (PC) by analogue to digital (AD) breakfast without caffeine-containing beverages. The study conversion (1 kHz per channel) for offline determination of took place in the intensive care unit ward to guarantee IBI length. Ventilatory frequency was assessed by inductive optimal monitoring. Two peripheral venous lines were plethysmography. Pulse oximetry was monitored continuinserted into antecubital veins. Subjects were in supine ously and standard cuff AP intermittently (Dinamap, position throughout the experiment. The sequence of interCriticon, Florida, USA) for safety reasons. ventions is illustrated in Figure 1 .
Five successive periods were studied (see Fig. 1 ). The
Beat-to-beat analysis
first was a 60-min control period. During the second experimental period, midazolam 0.02 mg kg -1 was adminis-APV was calculated by fast Fourier transform (FFT) after equidistant representation of systolic AP data. 9 HRV was tered i.v., half of the dose as a bolus (0.01 mg kg -1 over 2 min) followed by continuous infusion of the remainder determined by low-pass filtering of the event series (LPFES method), as suggested by Rompelman, Snijders and van score is defined as follows: awake levels-(1) anxious and/ Spronsen. 10 APV and HRV were analysed for each of the or agitated; (2) co-operative, oriented, and tranquil; (3) following frequency bands: total band (0.02-0.5 Hz), high responds to commands; asleep levels-(4) quiescent with band (0.15-0.4 Hz), low band (0.07-0.14 Hz) and very low brisk response to light glabelar tap or loud auditory stimulus; band (0.02-0.06 Hz). HRV was adjusted to mean HR (5) sluggish response to light glabelar tap or loud auditory (modulation index, MI) as suggested previously. 11 All stimulus; and (6) no response. Scores of the two physicians variables were log-transformed to achieve normally distrib-were averaged. uted measures; HRV was expressed as ln MI 2 and APV as ln mm Hg 2 .
Statistical analysis
Transfer function analysis of beat-to-beat changes in IBI All statistical calculations were performed using SAS softlength and systolic AP data was performed using ACTS ware (release 6.12, SAS Institute Inc., Cary, NC, USA). software in accordance with previous publications. 6 12 13 Data are reported as mean (SEM). A repeated measures The modulus gain function was calculated over the fre-analysis of variance (SAS General Linear Model Procedure) quency range 0.02-0.5 Hz. The modulus gain function is was applied for multivariate testing of dose and drug effects. expressed in ms mm Hg -1 . For further statistical analysis, Averages of the Greenhouse-Geisser and Huynh-Feldt this function was adjusted to the coherence function, as adjusted P values are reported. 15 Contrasts between the suggested previously. 6 For graphical illustration of the third midazolam infusion period and flumazenil period were modulus gain function over the entire spectrum (0.02-0.5 constructed a priori (non-adjusted P values are reported in Hz), it was not adjusted to the coherence function between tables). All testing was two-tailed. PϽ0.05 was considered systolic AP and IBI length. We calculated separately the significant. low and high frequency components of the transfer function between systolic AP and IBI by integrating the modulus gain function over the low and high frequency bands, thus Results resulting in two variables (LF and HF components of the Midazolam and flumazenil were well tolerated by all subjects. transfer function between systolic AP and IBI). All variables No adverse events occurred during infusion and pulse oxiwere first derived for each 5-min block and then averaged metry revealed no clinically significant desaturation. Plasma between both blocks. midazolam concentrations at 30 and 60 min for each period are shown in Table 1 . Ramsay sedation scores increased with
EEG registration
higher doses of midazolam (baseline, median 2 (range 1-2); At the same time as cardiovascular variables were assessed, midazolam infusion of 0.02 mg kg -1 , 3 (2-4); midazolam EEG data were recorded from FP1-T3, T3-O1, FP2-T4, infusion of 0.06 mg kg -1 , 4 (4-5); midazolam infusion of T4-O2 (according to the International 10-20 System) with 0.14 mg kg -1 , 5 (4-6)) and decreased during flumazenil infuthe subject's eyes closed. Ground was placed at the central sion (3 (2-4) ). forehead. The skin was prepared to yield impedance values Power analysis of EEG data revealed decreasing α power, lower than 3 kW at each electrode site. A Moberg Neurotrac increasing δ power and increasing β1 power. All of the above II Continuous EEG Monitor (frequency range 0.5-45 Hz) effects were reversible during infusion of flumazenil was used to display and store (AD conversion 12 bit, 128 (Table 2 ). Hz) EEG data in consecutive 2-s epochs. To minimize AP, HR and respiratory frequency data are shown in artefacts, a 50-Hz notch filter was used. Variables analysed Table 3 . HR and respiratory frequency increased whereas by FFT for each epoch included absolute power in the AP remained unaffected during infusion of midazolam. following frequency bands: entire spectrum (1.0-30.0 Hz), In general, there was an increase in HRV and APV (Table  α Subjective sedation score not the case for the high frequency component. Figure 3 indicates that infusion of flumazenil induced an increase in Subjects were rated by two physicians according to a scale proposed by Ramsay and colleagues. 14 The Ramsay sedation the fast component of the transfer function between AP showed an increase in the last midazolam infusion period) during Data are mean (SEM).
midazolam infusion, and increments during flumazenil infusion.
baroreflex efferents are divided into two pathways: the fast parasympathetic branch to the sinus node and to other cardiac regions via the vagus nerve and the sympathetic branch, which is characterized by a slower signal transduction to cardiac and vascular effector cells. High frequency components (greater than 0.15 Hz) of AP and HR variations, therefore, cannot be of sympathetic origin. Modern signal analysis techniques, such as the transfer function analysis of beat-to-beat AP and HR data which were used in our investigation, make it possible to estimate the magnitude of the transfer function between AP and HR data separately in the vagally dominated high frequency range and in the low frequency range (which is believed to be of mixed sympathetic and parasympathetic origin). 24 We believe that High and low frequency components of the transfer cated decreased baroreflex sensitivity after administration of benzodiazepine partial inverse agonists. 31 Thus this issue function between AP and IBI are influenced by baroreflex HR control. 5 16 17 Indeed, transfer function analysis may be remains to be studied.
Traditional determination of baroreflex sensitivity in used to estimate baroreflex sensitivity. 6 12 18-23 Frequently, the magnitudes of the high and low frequency components humans does not distinguish between sympathetic and parasympathetic effects of HR control. 32 In summary, our investigation in healthy young volunteers series of point events particularly for heart rate variability data. 
